Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
16hon MSN
PPF, SSY and other small savings schemes: Why they matter beyond tax benefits under the new regime
Many investors assume schemes like PPF and SSY are only worth considering if they reduce taxable income. That used to be true ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results